Replies to post #25066 on Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

I've been riding Genfit, on Paris stock Exchange.

it's head to head with Intercept to be first in the market for NASH.

phase3, pure development stage biotech, cash likely to last until final approval,

potential market it's huge, but company currently has no revenue, no earnings, just cash burn; if approved will be hitting the market in 2019 and the market cap is....

...980Mln euro, 31mln shares !!!

rumor of a potential ascquisition sent the shares from 20 to 35 Yesterday...

more than one here would say it was corretly priced at 10, where it was last october, beacause it has just uncertainties on its future, nothing sure.

Hmmmm... nice... just like IPCI.

[Tekterra]

It would be no surprises to see more mergers in the NASH side of things. All those companies trying to race to market first. If you got the cash to take positions in Genfit too it's a good bet. There are whole lot of trading on speculations in NASH stocks. Trading much higher than actual value.